LYMPHOPROLIFERATIVE DISEASE IN HUMAN 11. ROLE OF HOST AND DONOR FACTORS IN TUMOR GENERATION PERIPHERAL-BLOOD-MONONUCLEAR-CELL-INJECTED SCID MICE.

lntraperitoneal injection of lymphoid cells from EBV+ donors into SCID mice might provide a useful tool for studying the pathways of B-cell lymphomagenesis in man. Since previous studies showed that donor T cells greatly favor B-cell proliferation and tumor generation in this model, we addressed the host and donor factors involved in limiting or promoting lymphoma development. The number of EBV-infected B-cell precursors was crucial, since purified B lymphocytes, which alone were unable to generate tumors, underwent expansion and established tumor masses when the animals were inoculated with an EBV-containing supernatant. Host factors were critical in limiting tumor development; in vivo NK-cell removal allowed purified B cells to expand and proceed to tumors in the absence of T lymphocytes, whereas potentiation of mouse NK-cell activity prevented tumor generation in PBMC-and LCL-injected animals. The T-cell-derived factors that favor lymphomagenesis could not be identified; IL-2, IL-4, IL-6, and soluble CD23 were not able to promote B-cell expansion, and treatment of PBMC-injected mice with the relevant anti-cytokine anti-sera did not counteract lymphoma development. These experiments also showed that IL-6 plays a minor role, if any, in B-cell lymphopro-liferation in this model. Our data indicate that reconstitution of SCID mice with PBMC from EBV+ donors may constitute a useful model for determining the events involved in lymphoma-genesis in humans, provided that strict control of all the experimental variables is guaranteed.

[1]  A. Del Mistro,et al.  Properties of tumors arising in SCID mice injected with PBMC from EBV-positive donors. , 1994, Leukemia.

[2]  H. Ochs,et al.  Specific antibody production to a recall or a neoantigen by SCID mice reconstituted with human peripheral blood lymphocytes. , 1993, Journal of immunology.

[3]  P. Isaacson,et al.  The response of cells from low-grade B-cell gastric lymphomas of mucosa-associated lymphoid tissue to Helicobacter pylori , 1993, The Lancet.

[4]  T. J. Reed,et al.  Determination of B‐Cell Clonality in Paraffin‐Embedded Lymph Nodes Using the Polymerase Chain Reaction , 1993, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[5]  A. Del Mistro,et al.  Lymphoproliferative disease in human peripheral blood mononuclear cell- injected SCID mice. I. T lymphocyte requirement for B cell tumor generation , 1992, The Journal of experimental medicine.

[6]  T. Umemoto,et al.  Engraftment of human peripheral blood leukocytes into severe combined immunodeficient mice results in the long term and dynamic production of human xenoreactive antibodies. , 1992, Journal of immunology.

[7]  S. Hsu,et al.  Functional heterogeneity and pathogenic significance of interleukin-6 in B-cell lymphomas. , 1992, The American journal of pathology.

[8]  H. Nakamine,et al.  Hemagglutination and graft-versus-host disease in the severe combined immunodeficiency mouse lymphoproliferative disease model. , 1992, The American journal of pathology.

[9]  T. Kipps,et al.  Heterogeneity among Epstein-Barr virus-seropositive donors in the generation of immunoblastic B-cell lymphomas in SCID mice receiving human peripheral blood leukocyte grafts. , 1992, Cancer research.

[10]  J. Braun,et al.  Limited B cell repertoire in severe combined immunodeficient mice engrafted with peripheral blood mononuclear cells derived from immunodeficient or normal humans. , 1991, The Journal of clinical investigation.

[11]  L. Young,et al.  Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man , 1991, The Journal of experimental medicine.

[12]  R. Fisher,et al.  Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. , 1990, The New England journal of medicine.

[13]  S. Steinberg,et al.  Development of non-Hodgkin lymphoma in a cohort of patients with severe human immunodeficiency virus (HIV) infection on long-term antiretroviral therapy. , 1990, Annals of internal medicine.

[14]  G. Forni,et al.  Expression of an exogenous interleukin 6 gene in human Epstein Barr virus B cells confers growth advantage and in vivo tumorigenicity , 1990, The Journal of experimental medicine.

[15]  G. Tosato,et al.  Identification of interleukin-6 as an autocrine growth factor for Epstein-Barr virus-immortalized B cells , 1990, Journal of virology.

[16]  D. Nadal,et al.  Role of Epstein-Barr virus and interleukin 6 in the development of lymphomas of human origin in SCID mice engrafted with human tonsillar mononuclear cells. , 1992, The Journal of general virology.

[17]  R. Schwartz,et al.  Immunologic induction of malignant lymphoma: identification of donor and host tumors in the graft-versus-host model. , 1975, Journal of the National Cancer Institute.